In global terms, BRD treatment and metaphylaxis represents the most lucrative market for the veterinary pharmaceutical industn The Holy Grail is the development of antimicrobials that require a single administration that provides an extended durationof activity But how does plasma drug concentration relate to clinical outcome? How long should we wait to re-treat animals that appear to be non-responders? Also, is there a risk that these long acting drugs will encourage development of antimicrobial resistance? In this session we will address these questions and dispel 5 antimicrobial treatment myths relating to combination therapy, route of drug administration, class switching and using body temperature as a basis for treatment.
展开▼
